home / stock / inva / inva quote
Last: | $15.20 |
---|---|
Change Percent: | 0.2% |
Open: | $15.18 |
Close: | $15.17 |
High: | $15.295 |
Low: | $15.04 |
Volume: | 250,371 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$15.2 | $15.18 | $15.17 | $15.295 | $15.04 | 250,371 | 04-24-2024 |
$15.17 | $14.95 | $15.17 | $15.345 | $14.89 | 1,492,750 | 04-23-2024 |
$14.93 | $14.98 | $14.93 | $15.155 | $14.83 | 777,050 | 04-22-2024 |
$14.95 | $14.69 | $14.95 | $15.015 | $14.69 | 635,953 | 04-19-2024 |
$14.69 | $14.49 | $14.69 | $14.71 | $14.44 | 636,366 | 04-18-2024 |
$14.48 | $14.48 | $14.48 | $14.63 | $14.35 | 520,564 | 04-17-2024 |
$14.47 | $14.4 | $14.47 | $14.55 | $14.325 | 499,195 | 04-16-2024 |
$14.4 | $14.58 | $14.4 | $14.73 | $14.36 | 552,445 | 04-15-2024 |
$14.63 | $14.68 | $14.63 | $14.68 | $14.485 | 456,046 | 04-12-2024 |
$14.71 | $14.66 | $14.71 | $14.74 | $14.53 | 343,308 | 04-11-2024 |
$14.6 | $14.51 | $14.6 | $14.705 | $14.46 | 641,740 | 04-10-2024 |
$14.72 | $14.76 | $14.72 | $14.88 | $14.68 | 331,397 | 04-09-2024 |
$14.73 | $14.69 | $14.73 | $14.79 | $14.59 | 444,875 | 04-08-2024 |
$14.66 | $14.62 | $14.66 | $14.735 | $14.51 | 873,376 | 04-05-2024 |
$14.66 | $14.93 | $14.66 | $15.03 | $14.565 | 523,208 | 04-04-2024 |
$14.81 | $14.74 | $14.81 | $14.82 | $14.33 | 1,238,034 | 04-03-2024 |
$14.8 | $15.16 | $14.8 | $15.245 | $14.76 | 721,819 | 04-02-2024 |
$15.21 | $15.3 | $15.21 | $15.3 | $15.005 | 523,858 | 04-01-2024 |
$15.24 | $15.23 | $15.24 | $15.39 | $15.13 | 490,248 | 03-29-2024 |
$15.24 | $15.23 | $15.24 | $15.39 | $15.13 | 490,248 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Single-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be presented by the Global Antibiotic Research & Development Partnership (GARDP) in a Scientific S...
2024-04-12 13:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...